<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467984</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VECL002</org_study_id>
    <nct_id>NCT03467984</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants</brief_title>
  <official_title>A Single-blind, Multi-center, Randomized, Active-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Immunogenicity of Intramuscular Three Injections With LBVE(Multivalent Pneumococcal Conjugate Vaccine) Compared to Prevnar13 in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of LBVE (Multivalent
      Pneumococcal Conjugate Vaccine) in healthy infants.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving pneumococcal serotype-specific IgG &gt;= 0.35 ug/ml</measure>
    <time_frame>4 weeks after 3rd(last) vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pneumococcal serotype-specific IgG geometic mean concentration (GMC) ratios</measure>
    <time_frame>4 weeks after 3rd(last) vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving targeted pneumococcal serotype-specific opsonophagocytic assay (OPA) titer</measure>
    <time_frame>4 weeks after 3rd(last) vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal serotype-specific OPA geometic mean titer (GMT) ratios</measure>
    <time_frame>4 weeks after 3rd(last) vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited adverse events</measure>
    <time_frame>Baseline(pre-vaccination) up to 7 days after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>Baseline(pre-vaccination) up to 4 weeks after 3rd(last) vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Pneumococcal Infection</condition>
  <arm_group>
    <arm_group_label>LBVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants will receive a 0.5mL intramuscular injection of LBVE at 6,10 and 14 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants will receive a 0.5mL intramuscular injection of Prevnar13 at 6,10 and 14 weeks of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LBVE</intervention_name>
    <description>Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh</description>
    <arm_group_label>LBVE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar13</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh</description>
    <arm_group_label>Prevnar13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants of either sex who have reached at least 42 days (6 weeks) of age and
             not more than 56 days (8 weeks) of age at the time of enrollment.

          -  The parents or LAR(Legally authorized representative) able to understand and comply
             with planned study procedures.

          -  Signed informed consent by subject's parents or LAR(Legally authorized representative)

        Exclusion Criteria:

          -  Previously received any pneumococcal vaccine

          -  Receipt of immunoglobulin or blood-derived product before the study

          -  Known or suspected immune disorder, or received immunosuppressive therapy

          -  Known major congenital malformation or serious chronic disorder

          -  Participation in another interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>8 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 18, 2018</last_update_submitted>
  <last_update_submitted_qc>March 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

